Bristol-Myers Squibb Company (BMY)
NYSE • Healthcare
April 2, 2026 at 20:00 UTC
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is a biopharmaceutical enterprise that discovers, develops, and commercializes medicines in oncology, immunology, cardiovascular disease, and other therapeutic areas. Research programs span biologics and small molecules guided by translational science, clinical development, and collaborations with academic groups and biotechnology partners. Manufacturing and quality systems support global supply for hospitals and pharmacies, while medical affairs and patient services help clinicians use therapies appropriately. The company engages regulators and health systems across North America, Europe, and key international markets, aligning access strategies with local standards of care. Within the healthcare ecosystem, Bristol-Myers Squibb contributes targeted treatments and pursues pipelines intended to address complex, chronic conditions.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Bristol-Myers Squibb Company's Technical Indicators Summary
BMY exhibits a modestly bullish technical stance as the price sits above most moving averages, including the 200-day, and MACD and short-term momentum show constructive readings. Oscillators are neutral to mildly positive and ATR indicates subdued volatility, while ADX points to limited trend strength. On-balance volume is negative, which contrasts with the moving-average alignment and warrants attention, and the pivot lies above the market as a near-term resistance reference. Technical takeaway: moving averages and momentum lean bullish, but weak volume and modest trend strength temper conviction.
| Indicator | Value |
|---|---|
RSI (14) | 50.73 |
Stochastic %K (14, 3, 3) | 78.53 |
CCI (20) | 35.59 |
WPR (14) | -45.50 |
Momentum (10) | 1.49 |
MFI | 37.34 |
MACD Level (12, 26) | 0.15 |
Bollinger Bands | $56.95 - $61.70 |
ATR (14) | $1.45 (2.43%) |
ADX (14) | 15.45 |
OBV | -4,873,100 |
Classic Pivot Point | $61.61 |
Fibonacci Pivot Point | $61.61 |
Simple Moving Averages | $50.83 - $59.32(5 indicators) |
Exponential Moving Averages | $52.65 - $59.66(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
The day wrapped with BMY trading below yesterday’s close, never fully erasing the -2.45% gap down. End-of-session positioning for BMY remained put-heavy, pushing the ratio to 1.17. BMY declines as Lombard Odier trims its stake in Q4 and insider EVP Elkins sells, adding to caution after softer earnings.
Price Change
from $59.39 close
+$0.22
Trading Volume
Below avg (16.7M)
11.4M
vs S&P 500 Today
Underperforming Market
-1.61%
52-Week Position
Upper range
83.8%
Updated: April 3, 2026 at 20:09 UTC
Quote Summary
BMY Headlines
Fresh Valuation Checks Across Key Stocks
April 4, 2026
Colgate-Palmolive faces key board, dividend moves
March 26, 2026
AI, Capital Moves Shape Key Stock Narratives
March 15, 2026
Markets Swoon as Bitcoin, Tech and Crypto Firms Slide
February 5, 2026